Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus

Journal of Medicinal Chemistry

Volumn 52, Issue 15, 2009, Pages 4903-4910

  Wen, Wen Hsien ^a   Lin, Mengi ^b   Su, Ching Yao ^a,b   Wang, Shi Yun ^b   Cheng, Yih Shyun E ^b   Fang, Jim Min ^a,b   Wong, Chi Huey ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOMER; PORPHYRIN DERIVATIVE; SIALIDASE; SINGLET OXYGEN; UNCLASSIFIED DRUG; ZANAMIVIR; ZANAMIVIR PORPHYRIN CONJUGATE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NONHUMAN; SENSITIZATION; VIRUS INACTIVATION;

ANTIVIRAL AGENTS; ENZYME INHIBITORS; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PORPHYRINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 68549115376     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900515g     Document Type: Article

References (54)

1. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681-690.
2. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure - activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 1998, 41, 2451-2460.
3. Lew, W.; Chen, X.; Kim, C. U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000, 7, 663-672.
4. McClellan, K.; Perry, C. M. Oseltamivir: a review of its use in influenza. Drugs 2001, 61, 263-283.
5. von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
6. Taylor, N. R.; von Itzstein, M. Molecular modeling studies on ligand binding to salidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 1994, 37, 616-624.
7. von Itzstein, M.; Dyason, J. C.; Oliver, S. W.; White, H. F.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J. Med. Chem. 1996, 39, 388-391.
8. Dunn, C. J.; Goa, K. L. Zanamivir: a review of its use in influenza. Drugs 1999, 58, 761-784.
9. Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353, 1363-1373.
10. De Clercq, E. Antiviral agents actives against influenza A viruses. Nat. Rev. Drug Discovery 2006, 5, 1015-1025.
11. Schmidt, A. C. Antiviral therapy for influenza. Drugs 2004, 64, 2031-2046.
12. McKimm-Breschkin, J. L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 2000, 47, 1-17.
13. Gubareva, L. V.; Webster, R. G.; Hayden, F. G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 2001, 48, 3403-3408.
14. de Jong, M. D.; Tran, T. T.; Truong, H. K.; Vo, M.H.; Smith, G. J.; Nguyen, V. C.; Bach, V. C.; Phan, T. Q.; Do, Q. H.; Guan, Y.; Peiris, J. S.; Tran, T. H.; Farrar, J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353, 2667-2672.
15. Anne Moscona, M. D. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 2005, 353, 2633-2636.
16. Le, Q. M; Kiso, M.; Someya, K.; Sakai, Y. T.; Nguyen, T. H.; Nguyen, K. H.; Pham, N. D.; Ngyen, H. H.; Yamada, S.; Muramoto, Y.; Horimoto, T.; Takada, A.; Goto, H.; Suzuki, T.; Suzuki, Y.; Kawaoka, Y. Isolation of drug-resistant H5N1 virus. Nature 2005, 437, 1108.
17. Shie, J.-J.; Fang, J.-M.; Wang, S.-Y.; Tsai, K.-C.; Cheng, E. Y.-S.; Yang, A.-S.; Hsiao, S.-C.; Su, C.-Y.; Wong, C.-H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J. Am. Chem. Soc. 2007, 129, 11892-11893.
18. Shie, J.-J.; Fang, J.-M.; Wong, C.-H. A concise and flexible synthesis of the potent anti-influenza agents tamiflu and tamiphosphor. Angew. Chem., Int. Ed. 2008, 47, 5788-5791.
19. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J.; Russell, R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453, 1108-1261.
20. Dharan, N. J.; Gubareva, L. V.; Meyer, J. J.; Okomo-Adhiambo, M.; McClinton, R. C.; Marshall, S. A.; George, K.; Epperson, S.; Brammer, L.; Klimov, A. I.; Bresee, J. S.; Fry, A. M. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA, J. Am. Med. Assoc. 2009, 301, 1034-1041.
21. Weinstock, D.M.; Zuccotti, G. The evolution of influenza resistance and treatment. JAMA, J. Am. Med. Soc. 2009, 301, 1066-1069.
22. Andrews, D. M.; Cherry, P. C.; Humber, D. C.; Jones, P. S.; Keeling, S. P.; Martin, P. F.; Shawa, C. D.; Swanson, S. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (zanamivir) modified in the glycerol sidechain. Eur. J. Med. Chem. 1999, 34, 563-574.
23. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related zanamivir. Bioorg. Med. Chem. Lett. 2002, 12, 1925-1928.
24. Varghese, J. N.; Laver, W. G.; Colman, P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 1983, 303, 35-40.
25. Colman, P. M.; Varghese, J. N.; Laver, W. G. Structure of the catalytic and antigenic sites in the influenza virus neuraminidase. Nature 1983, 303, 41-44.
26. Macdonald, S. J. F.; Watson, K. G.; Cameron, R.; Chalmers, D. K.; Demaine, D. A.; Fenton, R. J.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; Mason, A. M.; Nguyen, V.; Owens, I. J.; Parry, N.; Reece, P. A.; Shanahan, S. E.; Smith, D.; Wu, W.-Y.; Tucker, S. P. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 2004, 48, 4542-4549.
27. Watson, K. G.; Cameron, R.; Fenton, R. J.; Gower, D.; Hamilton, S.; Jin, B.; Krippner, G. Y.; Luttick, A.; McConnell, D.; Macdonald, S. J. F.; Mason, A. M.; Nguyen, V.; Tucker, S. P.; Wu, W.-Y. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg. Med. Chem. Lett. 2004, 14, 1589-1592.
28. Macdonald, S. J.; Cameron, R.; Demaine, D. A.; Fenton, R. J.; Foster, G.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Hill, A. P.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; McKimm-Breschkin, J.; Mills, G.; Nguyen, V.; Owens, I. J.; Parry, N.; Shanahan, S. E.; Smith, D.; Watson, K. G.; Wu, W. Y.; Tucker, S. P. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 2005, 48, 2964-2971.
29. Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H.; Kubo, S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53, 186-192.
30. Masuda, T.; Yoshida, S.; Arai, M.; Kanedo, S.; Yamashita, M.; Honda, T. Synthesis and anti-influenza evaluation of polyvalent salidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Chem. Pharm. Bull. 2003, 51, 1386-1398.
31. Bonnett, R. Photosensitizers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem. Soc. Rev. 1995, 24, 19-33.
32. Macdonal, I. J.; Dougherty, T. J. Basic principles of photodynamic therapy. J. Porphyrins Phthalocyanines 2001, 5, 105-129.
33. Castano, A. P.; Demidova, T. N.; Hambline, M. R. Mechanism in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization. Photodiagn. Photodynam. Ther. 2004, 1, 279-293.
34. Hamblin, M. R.; Hasan, T. Photodynamic therapy: a new anti-microbial approach to infectious disease?. Photochem. Photobiol. Sci. 2004, 3, 436-450.
35. O'Riordan, K.; Akilov, O. E.; Hasan, T. The potential for photodynamic therapy in the treatment of localized infections. Photodiagn. Photodynam. Ther. 2005, 2, 247-262.
36. Berthiaume, F.; Reiken, S.; Toner, M.; Tompkins, R.; Yarmush, M. Antibody-targeted photolysis of bacteria in vivo. Biotechnology 1994, 12, 703-706.
37. Wainwright, M. Photoinactivation of Viruses. Photochem. Photobiol. Sci. 2004, 3, 406-411.
38. Abramson, A. L.; Shikowitz, M. J.; Mullooly, V. M.; Steinberg, B. M.; Amella, C. A.; Rothstein, H. R. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch. Otolaryngol. Head Neck Surg. 1992, 118, 25-29.
39. Shikowitz, M, J.; Abramson, A. L.; Freeman, K.; Steinberg, B. M.; Nouri, M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998, 108, 962-967.
40. Shikowitz, M. J.; Abramson, A. L.; Steinberg, B. M.; DeVoti, J.; Bonagura, V. R.; Mullooly, V.; Nouri, M.; Ronn, A. M.; Inglis, A.; McClay, J.; Kathrine Freeman, K. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenul) chlorin for respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 2005, 131, 99-105.
41. Chandler, M.; Bamford, M. J.; Conroy, R.; Lamont, B.; Patel, B.; Patel, V. K.; Steeples, I. P.; Storer, R.; Weir, N. G.; Wright, M.; Williamson, C. J. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D- erythro-L-gluconononic acid. J. Chem. Soc., Perkin Trans. 1995, 1, 1173-1180.
42. Ying, L.; Gervay-Hague, J. One-bead-one-inhibitor-one-substrate screening of neuraminidase activity. ChemBioChem 2005, 6, 1857-1865.
43. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
44. Lee, B.-Y.; Parka, S. R.; Jeon, H. B.; Kim, K. S. A new solvent system for efficient synthesis of 1,2,3-triazoles. Tetrahedron Lett. 2006, 47, 5105-5109.
45. Lee, Y. C.; Lee, R. T. Carbohydrate - protein interactions: basis of glycobiology. Acc. Chem. Res. 1995, 28, 321-327.
46. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2755-2794.
47. Lundquist, J. J.; Toone, E. J. The cluster glycoside effect. Chem. Rev. 2002, 102, 555-578.
48. Ohuchi, M.; Asaoka, N.; Sakoi, T.; Ohuchi, R. Roles of neuraminidase in the initial stage of influenza virus infection. Microb. Infect. 2006, 8, 1287-1293.
49. Hoffman, A. S Origins and evolution of "controlled" drug delivery systems. J. Controlled Release 2008, 132, 153-163.
50. Deckert, P. M. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr. Drug Targets 2009, 10, 158-175.
51. Sirion, U.; Kim, H. J.; Lee, J. H.; Seo, J. W.; Lee, B. S.; Lee, S. J.; Oh, S. J.; Chi, D. Y. An efficient F-18 labeling method for PET study: Huisgen 1,3-dipolar cycloaddition of bioactive substances and F-18-labeled compounds. Tetrahedron Lett. 2007, 48, 3953-3957.
52. Bonger, K. M.; van den Berg, R. J. B. H. N.; Heitman, L. H.; Ijzerman, A. P.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homo-bivalent GnRHR ligands. Bioorg. Med. Chem. 2007, 15, 4841-4856.
53. Reed, L. J.; Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27, 493-497.
54. Burleson, F. G.; Chambers, T. M.; Wiedbrauk, D. L. Virology, a Laboratory Manual; Academic Press: San Diego, CA, 1992.